| HOME >> BIOLOGY >> TECHNOLOGY |
$15 million. There could be additional charges excluded from the
Company's GAAP net loss, to arrive at non-GAAP net income, which are
dependent on unknown future events and are difficult to predict and
estimate at this time.
Contacts:
Kyle Kuvalanka (investors) Jennifer Snyder (media)
(617) 761-4734 (617) 444-1439
Millennium Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
(in thousands, except per share
amounts)
Revenues:
Net product sales $70,360 $53,161 $191,550 $165,320
Revenue under strategic
alliances 10,628 17,196 38,168 82,990
Royalties 41,344 33,737 116,617 98,382
Total revenues 122,332 104,094 346,335 346,692
Costs and expenses:
Cost of sales 6,931 6,730 17,668 36,660
Research and development (Note 1) 72,551 73,436 217,162 235,343
Selling, general and
administrative (Note 1) 42,949 34,365 129,506 107,221
Restructuring 1,667 1,352 13,050 5,737
Amortization of intangibles 8,488 8,488 25,462 25,462
Total costs and expenses 132,586 124,371 402,848 410,423
Loss from operations (10,254) (20,277) (56,513) (63,731)
Other income (expense):
Investment in
'/>"/>
| SOURCE Millennium Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |